GlassScriptPhysician profile
Ronald Dwayne Delrie
NPI 1689850620
$24,302.31
in general payments reported to CMS, 2019-2025
85 companies · $3,917 in 2025
The $3,917 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,456 · 2020: $2,038 · 2021: $5,895 · 2022: $3,398 · 2023: $3,269 · 2024: $4,330 · 2025: $3,917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,634 · Long Term Medical Supply Or Device Loan: $1,446 · Education: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,633.69 |
| Long Term Medical Supply Or Device Loan | $1,446.39 |
| Education | $435.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $4,589.32 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Novartis Pharmaceuticals Corporation | $3,062.60 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,346.21 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $1,289.69 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Janssen Biotech, INC. | $880.68 | 2019-2025 | Darzalex, Talvey, Erleada |
| E.R. Squibb & Sons, L.L.C. | $839.71 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Pfizer INC. | $765.36 | 2019-2025 | |
| Genentech USA, INC. | $731.00 | 2019-2025 | Venclexta, Polivy, Lunsumio |
| Incyte Corporation | $657.77 | 2019-2025 | Jakafi, Jakafi, Monjuvi |
| Amgen INC. | $562.95 | 2019-2023 | Lumakras, Kyprolis |
| Veracyte, INC. | $510.48 | 2021-2024 | |
| Eisai INC. | $471.30 | 2019-2025 | |
| Glaxosmithkline, LLC. | $420.78 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Daiichi Sankyo INC. | $402.80 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Ipsen Biopharmaceuticals, INC | $393.01 | 2019-2025 | Onivyde, Somatuline Depot, Tazverik |
Show all 85 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Delrie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.